Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-1219 in HIV-1 infection
NCT07115368Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Aug 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GS-1219 in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Primary endpoint: Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (log10 Copies/mL) at Day 11 Relative to Historical Placebo Data. Started Aug 2025; status: terminated.
02
Drugs
GS-1219
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT07115368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07115368.